{
    "relation": [
        [
            "",
            "Everolimus",
            "Placebo"
        ],
        [
            "Description",
            "Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood concentrations.",
            "Matching Placebo was administered orally."
        ]
    ],
    "pageTitle": "Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00789828?sect=X025&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989142.82/warc/CC-MAIN-20150728002309-00249-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 866555443,
    "recordOffset": 866545806,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Patients in the study were randomized in a 2:1 ratio (Everolimus: Placebo). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Everolimus Drug: Placebo Interventions: Tuberous Sclerosis Subependymal Giant Cell Astrocytoma Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: March 1, 2012 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Everolimus \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 78 \u00a0 \u00a0 39 \u00a0 COMPLETED \u00a0 \u00a0 2 [1] \u00a0 8 \u00a0 NOT COMPLETED \u00a0 \u00a0 76 \u00a0 \u00a0 31 \u00a0 Ongoing in Double Blind \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 76 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 31 \u00a0 [1] Completed means discontinued the double-blind treatment period. \u00a0 Baseline Characteristics \u00a0 Show",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}